Bharat Immunologicals & Biologicals Corporation Limited reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported sales was INR 264.8 million compared to INR 247.02 million a year ago. Revenue was INR 267.99 million compared to INR 249.19 million a year ago. Net loss was INR 30.83 million compared to INR 93.61 million a year ago. Basic loss per share from continuing operations was INR 0.71 compared to INR 2.17 a year ago. Diluted loss per share from continuing operations was INR 0.71 compared to INR 2.17 a year ago.
For the six months, sales was INR 369.59 million. Revenue was INR 374.22 million. Net loss was INR 80.8 million. Basic loss per share from continuing operations was INR 1.87. Diluted loss per share from continuing operations was INR 1.87.